2021 in Review
2021 has been a banner year for science. With your support, we opened a new laboratory for creating clinical-grade cells to treat blindness, created stem cell...
26 Results
Clear Filters
Persisting Even When a Pandemic Delays a PhD: Meet Jenna Hall
When COVID-19 hit, Jenna Hall’s plans were completely upended. Set to embark on a PhD at the University of Melbourne in Australia, border closures meant an...
Showing Up For Science: Highlights of the NYSCF Gala
On October 5th, celebrities, scientists, and supporters ‘showed up for science’ at the The 2021 New York Stem Cell Foundation Gala. Hosted by CNN’s Chief Medical...
Envisioning a Brighter Future for Macular Degeneration Patients: Experts Unpack the Path to a Cell Therapy
Age-related macular degeneration (AMD) is a leading cause of vision loss, and those over the age of 75 have a nearly 30% risk of being affected....
A Cell Therapy in Development at NYSCF Could Give AMD Patients Their Sight Back
For patients with age-related macular degeneration (AMD), a cell therapy in development at the NYSCF Research Institute could provide what sounds like a miracle: the restoration...
NYSCF Advances Toward a Cell Therapy for Age-Related Macular Degeneration
The New York Stem Cell Foundation (NYSCF) today announced that they are developing a stem cell therapy to treat patients suffering from age-related macular degeneration (AMD)....
A Clearer Window Into Disease: Meet the Opera Phenix Microscope
At the root of every major disease of our time is the simple question: what is going wrong with our cells? Once scientists know exactly how...
Tackling COVID, Promoting Health Equity, and Delivering on the Promise of Regenerative Medicine: Highlights of the 2020 NYSCF Conference
“My oldest son, Andrew, is a cancer survivor,” said Tony Coles, MD, PhD, CEO of Cerevel Therapeutics. “He was afflicted with non-Hodgkins lymphoma when he...
Building Bruch’s Membrane to Better Understand Macular Degeneration
The Context: Age-related macular degeneration (AMD) results from the death of retinal pigmented epithelial cells (RPEs) in the eye. Bruch’s membrane is a structure that sits...
NYSCF Collaboration Identifies Promising Drug for Treating Most Common Form of Macular Degeneration
The Context: Age-related macular degeneration (AMD) is a disease which affects 8 million Americans and can lead to severe vision loss due to death of retinal...
What’s Next for Regenerative Medicine? NYSCF Drives Discussions at the World Stem Cell Summit
Last week, thousands of researchers and thought leaders gathered at the annual Phacilitate Leaders World and World Stem Cell Summit in Miami to discuss recent advancements...
Translational Research Takes Center Stage at NYSCF Conference
“Medicine shouldn’t be one size fits all,” National Institutes of Health (NIH) Director Dr. Francis Collins told the audience of the NYSCF Conference last week. “Think...
Four NYSCF Innovators Featured In Nature Article on Embryonic Stem Cell Research
Over the past 20 years, embryonic stem cell (ESC) research has evolved from a brand new field with lots of promise to one that is actively...
NYSCF Innovator Pioneers Treatment To Restore Vision In Macular Degeneration Patients
Thanks to a groundbreaking new stem cell treatment, patients with age-related macular degeneration (AMD) are getting their sight back. This treatment was pioneered by the inaugural...
Cutting-Edge Research Highlights The NYSCF Conference
Leaders in stem cell biology and researchers at the forefront of translational medicine convened at the 2016 NYSCF Conference to discuss the latest advances in using...
Stem Cell Treatments
NYSCF does not treat patients with stem cell therapies. Please visit www.clinicaltrials.gov for a complete listing of clinical trials being conducted worldwide, or consult your physician. Stem cell research...
Stem Cells in Clinical Trials to Cure Blindness
In 2011 NYSCF awarded Dr. Pete Coffey the inaugural NYSCF–Robertson Stem Cell Prize for his pioneering work bringing stem cell therapies to patients with macular degeneration....
First Disease-Specific Stem Cell Line by SCNT
A team of scientists led by the NYSCF Research Institute’s Dr. Dieter Egli report the first ever patient-specific, diploid (i.e. with two sets of chromosomes, the...
Japan Grants Final Approval for iPS Clinical Trial to Treat Blindness
Japan's regulatory body has given final go-ahead for the first-ever clinical trial testing patient-derived stem cells to treat age-related macular degeneration (AMD), a common form of...
In Japan, iPS Cell Therapy Fast-Tracked to Clinic
Induced pluripotent stem (iPS) cells are slated to enter a clinical study in Japan for the treatment of age-related macular degeneration. Massayo Takahashi, an opthamologist at...
Researchers Develop Test to Pinpoint Transition in Degenerative Eye Disease
Approximately 20% of patients diagnosed with dry age-related macular degeneration develop the wet form, which leads to irreversible eye damage and eventual blindness. While the dry...
First Induced Pluripotent Stem Cell Model of Rare Eye Disease
David Gamm, MD, PhD, and University of Wisconsin colleagues report the first induced pluripotent stem (iPS) cell model of Best disease, a rare, genetic disorder that...
Dieter Egli Contributes to Study that Provides Evidence of iPS Cell Transplantation Efficacy for Vision Regeneration
Dieter Egli, a NYSCF Senior Research Fellow, contributed to a study published in Molecular Medicine that provides direct evidence of sight-loss recovery using induced pluripotent stem...
Dieter Egli Contributes to Study that Provides Evidence of iPS Cell Transplantation Efficacy for Vision Regeneration
Dieter Egli, a NYSCF Senior Research Fellow, contributed to a study published in Molecular Medicine that provides direct evidence of sight-loss recovery using induced pluripotent stem...
British Scientist Working To Cure Common Form Of Blindness Named Recipient Of Inaugural NYSCF – Robertson Prize In Stem Cell Research
The New York Stem Cell Foundation (NYSCF) announced today that Dr. Peter J. Coffey, a British stem cell scientist working to cure blindness, will be the...